Emily Anne Scraggs
Directeur/Bestuurslid bij Talisman Therapeutics Ltd.
Profiel
Emily Anne Scraggs is the founder of Gen2 Neuroscience Ltd., which was founded in 2016.
She held the title of Director at the company.
Currently, she is a Director & Commercial Director at Talisman Therapeutics Ltd.
Actieve functies van Emily Anne Scraggs
| Bedrijven | Functie | Begin |
|---|---|---|
Talisman Therapeutics Ltd.
 Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Emily Anne Scraggs
| Bedrijven | Functie | Einde |
|---|---|---|
Gen2 Neuroscience Ltd.
 Gen2 Neuroscience Ltd. Pharmaceuticals: GenericHealth Technology Gen2 Neuroscience Ltd. develops novel treatments for dementia targeting abnormal forms of the essential cellular protein tau. The company was founded by Frederick John Livesey in January 07, 2016 and is headquartered in Manchester, the United Kingdom. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Gen2 Neuroscience Ltd.
Gen2 Neuroscience Ltd. Pharmaceuticals: GenericHealth Technology Gen2 Neuroscience Ltd. develops novel treatments for dementia targeting abnormal forms of the essential cellular protein tau. The company was founded by Frederick John Livesey in January 07, 2016 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | Health Technology |
